OncoCyte (NASDAQ:OCX) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 83.19 percent increase over losses of $(1.13) per share from the same period last year. The company reported quarterly sales of $2.32 million which beat the analyst consensus estimate of $154.50 thousand by 1.40K percent. This is a 1.22K percent increase over sales of $176.00 thousand the same period last year.